Table 2.
EULAR response | ||||
---|---|---|---|---|
No | Moderate | Good | P | |
RTX | ||||
Group A | 4 (16%) | 5 (20%) | 7 (28%) | 0.038 |
Group B | 6 (24%) | 2 (10%) | 1 (4%) | |
IFX | ||||
Group A | 2 (10%) | 5 (25%) | 2 (10%) | 0.002 |
Group B | 10 (50%) | 1 (5%) | 0 | |
ETN | ||||
Group A | 3 (16.67%) | 5 (27.78%) | 7 (38.89%) | 0.023 |
Group B | 3 (16.67%) | 0 | 0 | |
ADL | ||||
Group A | 2 (22.22%) | 1 (11.11%) | 5 (55.56%) | 0.194 |
Group B | 1 (11.11%) | 0 | 0 |
Differences between EULAR responses in group A and group B were tested using Kruskal-Wallis test, for each biologic agent.
RTX: rituximab; IFX: infliximab; ETN: etanercept; ADL: adalimumab.
Group A: detectable drug level; Group B: undetectable drug level.